3-Hydroxyphencyclidine (3-HPC), a breakdown product of phencyclidine (PCP), is growing attracting clinical scrutiny due to initial data suggesting unique pharmacological characteristics. Present analyses indicate that 3-HPC may display distinct responses on the nervous system, potentially contrib